Synopsis
Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Listed Dossiers
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide
2. 2-(4-(3-fluorobenzyloxy)benzylamino)propionamide
3. Fbap Methanesulfonate
4. Fce 26743
5. Fce 28073
6. Fce-26743
7. Fce-28073
8. Nw-1015
9. Pnu 151774e
10. Pnu-151774e
11. Safinamide
12. Safinamide Methanesulfonate
13. Xadago
1. 202825-46-5
2. Safinamide Mesilate
3. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamide Methanesulfonate
4. Pnu-151774e
5. Nw-1015
6. Safinamide (mesylate)
7. Safinamide Methanesulfonate
8. Pnu 151774e
9. Safinamide Mesylate [usan]
10. Fce-28073
11. Nw 1015
12. Safinamide Methansulfonate
13. Ys90v3dtx0
14. Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2s)-, Methanesulfonate (1:1)
15. 202825-46-5 (mesylate)
16. Safinamide Mesilate (jan)
17. Safinamide Mesylate (usan)
18. Safinamide Mesilate [jan]
19. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)-amino)propanamide Methanesulfonate
20. Chembl48582
21. (s)-2-[[4-[(3-fluorobenzyl)oxy]benzyl]amino]propanamide Methanesulfonate
22. Unii-ys90v3dtx0
23. Fce-28073(r-isomer)
24. Safinamidemesylate
25. Equfina (tn)
26. Xadago (tn)
27. Safinamide Mesylate Salt
28. Emd 1195686 Mesylate
29. Mls006010740
30. Schembl1665715
31. Dtxsid80942414
32. Hms3884o17
33. Safinamide Mesylate (fce28073)
34. Amy38833
35. Bcp16018
36. Ex-a2640
37. Hy-70057a
38. Mfcd15145475
39. S1472
40. Safinamide Mesilate [who-dd]
41. Akos015902297
42. Ccg-268636
43. Safinamide Methanesulfonate [mi]
44. Safinamide Mesylate [orange Book]
45. Ac-27739
46. As-75602
47. Pnu-151774e,fce28073
48. Smr004701699
49. Safinamide Mesylate Salt, >=98% (hplc)
50. Cs-0006742
51. Sw219452-1
52. D10191
53. J-013174
54. Q27294690
55. (s)-2[4-(3-fluorobenzyloxy)benzylamino]propanamide Methanesulfonate
56. (s)-(+)-2-(4-(3-fluorobenzyloxy) Benzylamino)propanamide, Methanesulfonate
57. (s)-2-((4-((3-fluorobenzyl)oxy)benzyl)amino)propanamidemethanesulfonate
58. (s)-2-[4-(3-fluorobenzyloxy)benzylamino]propanamide Methanesulfonate
59. (2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic Acid
60. Propanamide, 2-(((4-((3-fluorophenyl)methoxy)phenyl)methyl)amino)-, (s)-, Monomethanesulfonate
Molecular Weight | 398.5 g/mol |
---|---|
Molecular Formula | C18H23FN2O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 7 |
Exact Mass | 398.13117117 g/mol |
Monoisotopic Mass | 398.13117117 g/mol |
Topological Polar Surface Area | 127 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 438 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Xadago is indicated for the treatment of adult patients with idiopathic Parkinsons disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.
N04B
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34164
Submission : 2019-09-30
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2020-11-05
Pay. Date : 2020-09-28
DMF Number : 35201
Submission : 2020-09-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-11-05
Pay. Date : 2020-09-26
DMF Number : 34399
Submission : 2020-02-13
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-10-14
Pay. Date : 2020-09-09
DMF Number : 35179
Submission : 2020-09-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32225
Submission : 2018-02-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28157
Submission : 2014-06-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33725
Submission : 2019-03-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-10-15
Pay. Date : 2020-08-12
DMF Number : 34628
Submission : 2020-02-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-10-15
Pay. Date : 2020-08-27
DMF Number : 35138
Submission : 2020-09-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35719
Submission : 2021-03-31
Status : Active
Type : II
Registration Number : 230MF10101
Registrant's Address : Frankfurter Strasse 250 64293 Darmstadt Germany
Initial Date of Registration : 2018-08-02
Latest Date of Registration : 2018-08-02
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Date of Issue : 2025-02-27
Valid Till : 2028-02-26
Written Confirmation Number : WC-511n
Address of the Firm : Plot No. 80A, Road No.5, Jawaharlal Nehru Pharma City, E. Bonangi (V), Parawada ...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
Date of Issue : 2025-02-27
Valid Till : 2028-02-26
Written Confirmation Number : WC-0511
Address of the Firm : Plot No. 80A, Road No.5, Jawaharlal Nehru Pharma City, E. Bonangi (V), Parawada ...
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Survey no. 52,53,58,59,61 to 78,127&128, Pydibhimanvaram Village &Sy.No. 1,2,4t0...
Date of Issue : 2022-12-09
Valid Till : 2025-12-03
Written Confirmation Number : WC-0457
Address of the Firm : Sy No 544, 545 & 546, Bhiknoor (V), Bhiknoor (M), Kamareddy-503101, Telangana, I...
Date of Issue : 2022-11-02
Valid Till : 2025-07-02
Written Confirmation Number : WC-0182
Address of the Firm : Sy.No.239&240,Dothigudem Village,Pochampally MandalYadadri-Bhuvanagiri,Dist.-508...
Date of Issue : 2022-08-31
Valid Till : 2025-08-04
Written Confirmation Number : WC-0127
Address of the Firm : A1/B, SIPCOT Industrial Complex, Kudikadu, Cuddalore -607005
Registrant Name : Korea Ezai Co., Ltd.
Registration Date : 2020-06-24
Registration Number : Su140-6-ND
Manufacturer Name : Merck KGaA
Manufacturer Address : Frankfurter Straße 250 D-64293 Darmstadt, Germany
Registrant Name : Saehan Pharmaceutical Co., Ltd.
Registration Date : 2022-05-27
Registration Number : Su532-8-ND
Manufacturer Name : Optimus Drugs Private Limite...
Manufacturer Address : Sy. No. 239 & 240, Dothigudem Village, Pochampally Mandal, Yadadri-Bhuvanagiri Distri...
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-03-03
Registration Number : 434-52-ND
Manufacturer Name : Solara Active Pharma Science...
Manufacturer Address : A1/B, Sipcot Industrial Complex, Kudikadu Village Cuddalore-607 005, Tamil Nadu, Indi...
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2025-06-17
Registration Number : Number 173-58-ND
Manufacturer Name : Zhejiang Huahai Pharmaceutic...
Manufacturer Address : Chuannan Duqiao, Linhai, Zhejiang, 317016, China.
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2025-04-04
Registration Number : Thu 21-31-ND
Manufacturer Name : Honour Lab Limited Unit-IX
Manufacturer Address : Survey No. 332, 335, 336 & 341, Veliminedu Village, Chityal Mandal, Nalgonda District...
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Registrant Name : Hoosung Bio Co., Ltd.
Registration Date : 2025-05-09
Registration Number : Thu21-31-ND(1)
Manufacturer Name : Honour Lab Limited Unit-IX
Manufacturer Address : Survey No. 332, 335, 336 & 341, Veliminedu Village, Chityal Mandal, Nalgonda District...
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
NDC Package Code : 73435-012
Start Marketing Date : 2020-12-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42973-301
Start Marketing Date : 2019-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-492
Start Marketing Date : 2024-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 72640-005
Start Marketing Date : 2019-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59285-031
Start Marketing Date : 2020-07-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82708-0005
Start Marketing Date : 2021-03-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
About the Company : Polpharma API, part of a leading Polish pharmaceutical group, has over 70 years of experience in process development and cGMP manufacturing. We offer end-to-end solutions, from API...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and specialty chemicals & ingredients manufacturer with seven facilities set to global standards of safety and quality. With our offerings, Honour S...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Nantong Jinghua Pharmaceutical is a public pharmaceutical company that was established in 1957, owns about 302 staff, located in No. 20, 3 Haibin Road, Yanhai Economic Development ...
About the Company : The company was founded by a technocrat Mr. D. Kesava Reddy in the year 2005. The Managing Director Mr. D. Kesava Reddy along with other three Board of Directors involved in contro...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Pharmanovia will take over rights from CSL and will be responsible for all commercial and regulatory activities of Xadago (safinamide), for adult patients with idiopathic Parkinson's disease.
Lead Product(s): Safinamide Methanesulfonate
Therapeutic Area: Neurology Brand Name: Xadago
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Pharmanovia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2024
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pharmanovia
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
Details : Pharmanovia will take over rights from CSL and will be responsible for all commercial and regulatory activities of Xadago (safinamide), for adult patients with idiopathic Parkinson's disease.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 10, 2024
Details:
Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Lead Product(s): Safinamide Methanesulfonate
Therapeutic Area: Neurology Brand Name: Xadago
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Zambon Group SpA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Zambon Group SpA
Deal Size : Undisclosed
Deal Type : Agreement
Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia
Details : Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2023
Details:
Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Lead Product(s): Safinamide Methanesulfonate
Therapeutic Area: Neurology Brand Name: Xadago
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Newron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 05, 2021
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Di...
Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2021
Details:
Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
Lead Product(s): Safinamide Methanesulfonate
Therapeutic Area: Neurology Brand Name: Equfina
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 09, 2020
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eisai to Take Over Manufacturing and Marketing Approval for Equfina® 50 Mg Tablets (safinamide Me...
Details : Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
Product Name : Equfina
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 09, 2020
Details:
The marketing authorization application for safinamide in South Korea was submitted in July 2019, and through the approval of this application, South Korea became the first country in Asia outside of Japan to grant marketing approval for safinamide.
Lead Product(s): Safinamide Methanesulfonate
Therapeutic Area: Neurology Brand Name: Equfina
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 25, 2020
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai’s Equfina receives South Korean marketing approval to treat Parkinson’s disease
Details : The marketing authorization application for safinamide in South Korea was submitted in July 2019, and through the approval of this application, South Korea became the first country in Asia outside of Japan to grant marketing approval for safinamide.
Product Name : Equfina
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2020
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Colorcoat FC4S is used as a film coating agednt in various OSDs.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Granule / Pellet
Grade : Not Available
Brand Name : Colorcoat FC4S(Clear)
Application : Coating Systems & Additives
Excipient Details : Transparent Coating
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Colorcoat FC4W is used as a film coating agednt in various OSDs.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Dosage Form : Granule / Pellet
Grade : Not Available
Brand Name : Colorcoat FC4W(Clear)
Application : Coating Systems & Additives
Excipient Details : Transparent Coating
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Colorcoat FC4WS is used as a film coating agednt in various OSDs.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Colorcoat MB4S is used as a film coating agednt in various OSDs.
Dosage Form : Granule / Pellet
Grade : Not Available
Brand Name : Colorcoat MB4S(Clear)
Application : Coating Systems & Additives
Excipient Details : Transparent Coating
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Moisture Barrier Coating
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Colorcoat SC4S is used as a coating agent in various OSDs.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Coating Systems & Additives
Excipient Details : Colorcoat SC4W is used as a coating agent in various OSDs.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
95
PharmaCompass offers a list of Safinamide Methanesulfonate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Safinamide Methanesulfonate manufacturer or Safinamide Methanesulfonate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Safinamide Methanesulfonate manufacturer or Safinamide Methanesulfonate supplier.
PharmaCompass also assists you with knowing the Safinamide Methanesulfonate API Price utilized in the formulation of products. Safinamide Methanesulfonate API Price is not always fixed or binding as the Safinamide Methanesulfonate Price is obtained through a variety of data sources. The Safinamide Methanesulfonate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Safinamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Safinamide, including repackagers and relabelers. The FDA regulates Safinamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Safinamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Safinamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Safinamide supplier is an individual or a company that provides Safinamide active pharmaceutical ingredient (API) or Safinamide finished formulations upon request. The Safinamide suppliers may include Safinamide API manufacturers, exporters, distributors and traders.
click here to find a list of Safinamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Safinamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Safinamide active pharmaceutical ingredient (API) in detail. Different forms of Safinamide DMFs exist exist since differing nations have different regulations, such as Safinamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Safinamide DMF submitted to regulatory agencies in the US is known as a USDMF. Safinamide USDMF includes data on Safinamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Safinamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Safinamide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Safinamide Drug Master File in Japan (Safinamide JDMF) empowers Safinamide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Safinamide JDMF during the approval evaluation for pharmaceutical products. At the time of Safinamide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Safinamide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Safinamide Drug Master File in Korea (Safinamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Safinamide. The MFDS reviews the Safinamide KDMF as part of the drug registration process and uses the information provided in the Safinamide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Safinamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Safinamide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Safinamide suppliers with KDMF on PharmaCompass.
A Safinamide written confirmation (Safinamide WC) is an official document issued by a regulatory agency to a Safinamide manufacturer, verifying that the manufacturing facility of a Safinamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Safinamide APIs or Safinamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Safinamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Safinamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Safinamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Safinamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Safinamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Safinamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Safinamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Safinamide suppliers with NDC on PharmaCompass.
Safinamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Safinamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Safinamide GMP manufacturer or Safinamide GMP API supplier for your needs.
A Safinamide CoA (Certificate of Analysis) is a formal document that attests to Safinamide's compliance with Safinamide specifications and serves as a tool for batch-level quality control.
Safinamide CoA mostly includes findings from lab analyses of a specific batch. For each Safinamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Safinamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Safinamide EP), Safinamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Safinamide USP).